drugset
drugset / Trial / NCT02819271

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

NCT02819271 ↗

Phase 1 Completed 80 enrolled Bristol-Myers Squibb Cardioxyl Pharmaceuticals, Inc · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.

Timeline

Start
2014-02
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject cimlanod Other / unclassified — Intravenous

Indications

heart failure